361 related articles for article (PubMed ID: 19156355)
21. Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study.
Kemner JE; Starr HL; Ciccone PE; Hooper-Wood CG; Crockett RS
Adv Ther; 2005; 22(5):498-512. PubMed ID: 16418159
[TBL] [Abstract][Full Text] [Related]
22. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis.
Cheng JY; Chen RY; Ko JS; Ng EM
Psychopharmacology (Berl); 2007 Oct; 194(2):197-209. PubMed ID: 17572882
[TBL] [Abstract][Full Text] [Related]
24. Atomoxetine treatment outcomes in adolescents and young adults with attention-deficit/hyperactivity disorder: results from a post hoc, pooled analysis.
Adler LA; Wilens T; Zhang S; Dittmann RW; D'Souza DN; Schuh L; Durell TM
Clin Ther; 2012 Feb; 34(2):363-73. PubMed ID: 22285724
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of atomoxetine hydrochloride in Korean adults with attention-deficit hyperactivity disorder.
Lee SI; Song DH; Shin DW; Kim JH; Lee YS; Hwang JW; Park TW; Yook KH; Lee JI; Bahn GH; Hirata Y; Goto T; Takita Y; Takahashi M; Lee S; Treuer T
Asia Pac Psychiatry; 2014 Dec; 6(4):386-96. PubMed ID: 25345739
[TBL] [Abstract][Full Text] [Related]
26. A randomized controlled trial investigation of a non-stimulant in attention deficit hyperactivity disorder (ACTION): rationale and design.
Tsang TW; Kohn MR; Hermens DF; Clarke SD; Clark CR; Efron D; Cranswick N; Lamb C; Williams LM
Trials; 2011 Mar; 12():77. PubMed ID: 21396130
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled, Forced-Dose Clinical Study.
Weisler RH; Greenbaum M; Arnold V; Yu M; Yan B; Jaffee M; Robertson B
CNS Drugs; 2017 Aug; 31(8):685-697. PubMed ID: 28712074
[TBL] [Abstract][Full Text] [Related]
28. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
[TBL] [Abstract][Full Text] [Related]
29. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study.
Michelson D; Faries D; Wernicke J; Kelsey D; Kendrick K; Sallee FR; Spencer T;
Pediatrics; 2001 Nov; 108(5):E83. PubMed ID: 11694667
[TBL] [Abstract][Full Text] [Related]
30. Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: a 6-week, randomized, placebo-controlled, double-blind trial in Russia.
Martenyi F; Zavadenko NN; Jarkova NB; Yarosh AA; Soldatenkova VO; Bardenstein LM; Kozlova IA; Neznanov NG; Maslova OI; Petrukhin AS; Sukchotina NK; Zykov VP
Eur Child Adolesc Psychiatry; 2010 Jan; 19(1):57-66. PubMed ID: 19568826
[TBL] [Abstract][Full Text] [Related]
31. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
Shang CY; Pan YL; Lin HY; Huang LW; Gau SS
J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):566-73. PubMed ID: 26222447
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder.
Biederman J; Heiligenstein JH; Faries DE; Galil N; Dittmann R; Emslie GJ; Kratochvil CJ; Laws HF; Schuh KJ;
Pediatrics; 2002 Dec; 110(6):e75. PubMed ID: 12456942
[TBL] [Abstract][Full Text] [Related]
33. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
Dittmann RW; Schacht A; Helsberg K; Schneider-Fresenius C; Lehmann M; Lehmkuhl G; Wehmeier PM
J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):97-110. PubMed ID: 21488751
[TBL] [Abstract][Full Text] [Related]
34. Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder.
Price MZ; Price RL
CNS Drugs; 2023 Jul; 37(7):655-660. PubMed ID: 37430151
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and Safety of a Long-Acting Multilayer-Release Methylphenidate Formulation (PRC-063) in the Treatment of Adolescent Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Clinical Trial with a 6-Month Open-Label Extension.
Weiss MD; Cutler AJ; Kollins SH; Donnelly GAE
J Child Adolesc Psychopharmacol; 2021 Nov; 31(9):610-622. PubMed ID: 34637343
[No Abstract] [Full Text] [Related]
36. A randomized, double-blind, placebo-controlled study of atomoxetine in Japanese children and adolescents with attention-deficit/hyperactivity disorder.
Takahashi M; Takita Y; Yamazaki K; Hayashi T; Ichikawa H; Kambayashi Y; Koeda T; Oki J; Saito K; Takeshita K; Allen AJ
J Child Adolesc Psychopharmacol; 2009 Aug; 19(4):341-50. PubMed ID: 19702486
[TBL] [Abstract][Full Text] [Related]
37. Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetine.
Perwien AR; Faries DE; Kratochvil CJ; Sumner CR; Kelsey DK; Allen AJ
J Dev Behav Pediatr; 2004 Aug; 25(4):264-71. PubMed ID: 15308927
[TBL] [Abstract][Full Text] [Related]
38. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.
Roskell NS; Setyawan J; Zimovetz EA; Hodgkins P
Curr Med Res Opin; 2014 Aug; 30(8):1673-85. PubMed ID: 24627974
[TBL] [Abstract][Full Text] [Related]
39. Does atomoxetine improve executive function, inhibitory control, and hyperactivity? Results from a placebo-controlled trial using quantitative measurement technology.
Wehmeier PM; Schacht A; Ulberstad F; Lehmann M; Schneider-Fresenius C; Lehmkuhl G; Dittmann RW; Banaschewski T
J Clin Psychopharmacol; 2012 Oct; 32(5):653-60. PubMed ID: 22926599
[TBL] [Abstract][Full Text] [Related]
40. A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability.
Treuer T; Gau SS; Méndez L; Montgomery W; Monk JA; Altin M; Wu S; Lin CC; Dueñas HJ
J Child Adolesc Psychopharmacol; 2013 Apr; 23(3):179-93. PubMed ID: 23560600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]